170 related articles for article (PubMed ID: 34670814)
1. KIF13B-mediated VEGFR2 trafficking is essential for vascular leakage and metastasis in vivo.
Waters SB; Dominguez JR; Cho HD; Sarich NA; Malik AB; Yamada KH
Life Sci Alliance; 2022 Jan; 5(1):. PubMed ID: 34670814
[TBL] [Abstract][Full Text] [Related]
2. KIF13B mediates VEGFR2 recycling to modulate vascular permeability.
Cho HD; Nhàn NTT; Zhou C; Tu K; Nguyen T; Sarich NA; Yamada KH
Cell Mol Life Sci; 2023 Mar; 80(4):91. PubMed ID: 36928770
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic Therapeutic Potential of Peptides Derived from the Molecular Motor KIF13B that Transports VEGFR2 to Plasmalemma in Endothelial Cells.
Yamada KH; Kang H; Malik AB
Am J Pathol; 2017 Jan; 187(1):214-224. PubMed ID: 27863212
[TBL] [Abstract][Full Text] [Related]
4. KIF13B regulates angiogenesis through Golgi to plasma membrane trafficking of VEGFR2.
Yamada KH; Nakajima Y; Geyer M; Wary KK; Ushio-Fukai M; Komarova Y; Malik AB
J Cell Sci; 2014 Oct; 127(Pt 20):4518-30. PubMed ID: 25128562
[TBL] [Abstract][Full Text] [Related]
5. VEGFR2 Trafficking by KIF13B Is a Novel Therapeutic Target for Wet Age-Related Macular Degeneration.
Waters SB; Zhou C; Nguyen T; Zelkha R; Lee H; Kazlauskas A; Rosenblatt MI; Malik AB; Yamada KH
Invest Ophthalmol Vis Sci; 2021 Feb; 62(2):5. PubMed ID: 33533881
[TBL] [Abstract][Full Text] [Related]
6. Endothelial SCUBE2 Interacts With VEGFR2 and Regulates VEGF-Induced Angiogenesis.
Lin YC; Chao TY; Yeh CT; Roffler SR; Kannagi R; Yang RB
Arterioscler Thromb Vasc Biol; 2017 Jan; 37(1):144-155. PubMed ID: 27834687
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
Lin YC; Liu CY; Kannagi R; Yang RB
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
[TBL] [Abstract][Full Text] [Related]
8. Endothelial Cells Regulate Physiological Cardiomyocyte Growth via VEGFR2-Mediated Paracrine Signaling.
Kivelä R; Hemanthakumar KA; Vaparanta K; Robciuc M; Izumiya Y; Kidoya H; Takakura N; Peng X; Sawyer DB; Elenius K; Walsh K; Alitalo K
Circulation; 2019 May; 139(22):2570-2584. PubMed ID: 30922063
[TBL] [Abstract][Full Text] [Related]
9. AIP1 functions as an endogenous inhibitor of VEGFR2-mediated signaling and inflammatory angiogenesis in mice.
Zhang H; He Y; Dai S; Xu Z; Luo Y; Wan T; Luo D; Jones D; Tang S; Chen H; Sessa WC; Min W
J Clin Invest; 2008 Dec; 118(12):3904-16. PubMed ID: 19033661
[TBL] [Abstract][Full Text] [Related]
10. VEGFR3 Modulates Vascular Permeability by Controlling VEGF/VEGFR2 Signaling.
Heinolainen K; Karaman S; D'Amico G; Tammela T; Sormunen R; Eklund L; Alitalo K; Zarkada G
Circ Res; 2017 Apr; 120(9):1414-1425. PubMed ID: 28298294
[TBL] [Abstract][Full Text] [Related]
11. Genetic reduction of vascular endothelial growth factor receptor 2 rescues aberrant angiogenesis caused by epsin deficiency.
Tessneer KL; Pasula S; Cai X; Dong Y; McManus J; Liu X; Yu L; Hahn S; Chang B; Chen Y; Griffin C; Xia L; Adams RH; Chen H
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):331-337. PubMed ID: 24311377
[TBL] [Abstract][Full Text] [Related]
12. Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis.
Chiodelli P; Rezzola S; Urbinati C; Federici Signori F; Monti E; Ronca R; Presta M; Rusnati M
Oncogene; 2017 Nov; 36(47):6531-6541. PubMed ID: 28783175
[TBL] [Abstract][Full Text] [Related]
13. VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesis.
Yang Z; Wang H; Jiang Y; Hartnett ME
Am J Pathol; 2014 Apr; 184(4):1230-1239. PubMed ID: 24630601
[TBL] [Abstract][Full Text] [Related]
14. Syntenin promotes VEGF-induced VEGFR2 endocytosis and angiogenesis by increasing ephrin-B2 function in endothelial cells.
Tae N; Lee S; Kim O; Park J; Na S; Lee JH
Oncotarget; 2017 Jun; 8(24):38886-38901. PubMed ID: 28418925
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor angiogenesis effect of a new compound: B-9-3 through interference with VEGFR2 signaling.
Ma Q; Chen W; Chen W
Tumour Biol; 2016 May; 37(5):6107-16. PubMed ID: 26611645
[TBL] [Abstract][Full Text] [Related]
16. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319
[TBL] [Abstract][Full Text] [Related]
17. MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway.
Lorenzon E; Colladel R; Andreuzzi E; Marastoni S; Todaro F; Schiappacassi M; Ligresti G; Colombatti A; Mongiat M
Oncogene; 2012 Jun; 31(26):3136-47. PubMed ID: 22020326
[TBL] [Abstract][Full Text] [Related]
18. Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling.
Awasthi N; Schwarz MA; Verma V; Cappiello C; Schwarz RE
Lab Invest; 2009 Jan; 89(1):38-46. PubMed ID: 19002109
[TBL] [Abstract][Full Text] [Related]
19. Rap1 promotes VEGFR2 activation and angiogenesis by a mechanism involving integrin αvβ₃.
Lakshmikanthan S; Sobczak M; Chun C; Henschel A; Dargatz J; Ramchandran R; Chrzanowska-Wodnicka M
Blood; 2011 Aug; 118(7):2015-26. PubMed ID: 21636859
[TBL] [Abstract][Full Text] [Related]
20. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2.
Zhang Z; Neiva KG; Lingen MW; Ellis LM; Nör JE
Cell Death Differ; 2010 Mar; 17(3):499-512. PubMed ID: 19834490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
